Latest in Cardiology from ACC.org

• The Evolut Low Risk Trial: Six-Year Outcomes of TAVR vs. SAVR in Patients at Low Surgical Risk
  The Evolut Low Risk trial was a prospective randomized trial that enrolled patients at low surgical risk with severe trileaflet aortic stenosis from 87 international sites between 2016 and 2019.
• Eagle’s Eye View: Maintaining Weight Loss With Tirzepatide
  In this week’s View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment.
• In Memoriam: William W. Parmley, MD, MACC
  William W. Parmley, MD, MACC, a transformative leader in cardiovascular medicine whose impact on the ACC spanned decades, passed away peacefully on May 23 at the age of 90, surrounded by his family.
• Ten Points to Remember From the Recent AHA Scientific Statement on "Cardiovascular Toxicity in Patients Treated for Childhood Cancer"
  Pediatric cardio-oncology has expanded in scope over the past several decades to address the ever-increasing issues related to cardiovascular disease (CVD) in patients with and survivors of cancer, related both to treatment modalities and the disease itself.
• ACCEL Lite: A Look At The ORBITA-CTO Trial
  n this interview, Allen J. Taylor, MD, FACC and John Davies, MBBS, PhD evaluate the ORBITA-CTO Trial.